A Phase I Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Trial Profile

A Phase I Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Bone cancer; Germ cell and embryonal neoplasms; Penile cancer; Prostate cancer; Renal cell carcinoma; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb; Exelixis
  • Most Recent Events

    • 02 Apr 2018 Planned primary completion date changed from 29 Dec 2017 to 30 Sep 2019.
    • 10 Feb 2018 Results of phase I plus expansion cohorts (n=75) presented at the 2018 Genitourinary Cancers Symposium
    • 07 Feb 2018 According to an Exelixis media release, the findings from this study will be presented at the 2018 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top